In the context of RCC, the activity of known regulators of apoptosis, such as Bcl-2, whose expression is usually not dysregulated in kidney neoplasms, can be modulated by pharmacological intervention, such as by the inhibition of cyclin-dependent kinase phosphates, such as cdc25. The gene discussed is BCL2; the disease is renal cell adenocarcinoma.